Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
R M StoneB L Powell

Abstract

Secondary acute myeloid leukemia (sAML), defined as AML arising after a prior myelodysplastic syndrome or after antineoplastic therapy, responds poorly to current therapies. It is often associated with adverse karyotypic abnormalities and overexpression of proteins that mediate drug resistance. We performed a phase III trial to determine whether induction therapy with cytarabine and amonafide L-malate, a DNA intercalator and non-ATP-dependent topoisomerase II inhibitor that evades drug resistance mechanisms, yielded a superior complete remission rate than standard therapy with cytarabine and daunorubicin in sAML. Patients with previously untreated sAML were randomly assigned at a one-to-one ratio to cytarabine 200 mg/m(2) continuous intravenous (IV) infusion once per day on days 1 to 7 plus either amonafide 600 mg/m(2) IV over 4 hours on days 1 to 5 (A + C arm) or daunorubicin 45 mg/m(2) IV over 30 minutes once per day on days 1 to 3 (D + C arm). The complete remission (CR) rate was 46% (99 of 216 patients) in A + C arm and 45% (97 of 217 patients) in D + C arm (P = .81). The 30- and 60-day mortality rates were 19% and 28% in A + C arm and 13% and 21% in D + C arm, respectively. Induction treatment with A + C did not improve th...Continue Reading

References

Jan 1, 1980·Cancer Chemotherapy and Pharmacology·M F BrañaA Jiménez
Apr 18, 2002·Leukemia·J M Rowe
Mar 6, 2007·Best Practice & Research. Clinical Haematology·Richard A Larson
Sep 11, 2007·Leukemia Research·Mydoanh ChauRobert L Capizzi
Sep 25, 2009·The New England Journal of Medicine·Bob LöwenbergUNKNOWN Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group
Sep 25, 2009·The New England Journal of Medicine·Hugo F FernandezMartin S Tallman
Jun 19, 2010·Blood·Jacob M Rowe, Martin S Tallman
Feb 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric J FeldmanArthur C Louie
Feb 16, 2013·Cancer Cell·Matthew S Davids, Anthony Letai

❮ Previous
Next ❯

Citations

Dec 15, 2015·Blood·Hervé Dombret, Claude Gardin
Oct 16, 2015·Hematology/oncology and Stem Cell Therapy·Edward A CopelanBelinda R Avalos
Nov 3, 2015·Leukemia Research·Joshua F Zeidner, Judith E Karp
Apr 27, 2010·Journal of Hematology & Oncology·Xiongpeng ZhuDelong Liu
Feb 1, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Yu HuangYan-Ru Fan
Oct 12, 2017·Expert Opinion on Pharmacotherapy·Tracy Murphy, Karen W L Yee
Oct 25, 2017·Current Hematologic Malignancy Reports·Rahul S Vedula, R Coleman Lindsley
Jul 20, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey E LancetBruno C Medeiros
Jan 24, 2019·Expert Review of Clinical Pharmacology·Juan Eduardo Megías-VericatPau Montesinos
May 18, 2019·Organic & Biomolecular Chemistry·Iqubal SinghKamaldeep Paul
Jun 1, 2017·American Society of Clinical Oncology Educational Book·Courtney D DiNardoBruno C Medeiros
Jan 23, 2019·Annals of Hematology·Edna CheungBernard L Marini
Oct 2, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Joshua F ZeidnerB Douglas Smith
Jan 28, 2021·American Journal of Hematology·Daniel R RichardsonJoshua F Zeidner
Feb 21, 2021·Current Hematologic Malignancy Reports·Daniel R RichardsonJoshua F Zeidner
Nov 15, 2017·European Journal of Medicinal Chemistry·Meng LiSongqiang Xie
Jul 7, 2021·Expert Opinion on Emerging Drugs·Davis F Phillips, Joshua F Zeidner
Jul 28, 2021·Bioorganic Chemistry·Shan-Shan WangKe-Rang Wang
Jun 6, 2018·Journal of Medicinal Chemistry·Wei HuXun Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.